Weight‐loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 ( rs1800497 ): A pilot study
- 8 January 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (3) , 850-853
Abstract
Naltrexone/bupropion (NB) is a US Food and Drug Administration‐approved antiobesity medication. Clinical trials have shown variable weight loss, with responders and non‐responders. NB is believed to act on central dopaminergic pathways to suppress appetite. The Taq1A polymorphism near DRD2 (rs1800497) is associated with the density of striatal dopamine D2 receptors, with individuals carrying the A allele (AA or AG; termed A1+) having 30%‐40% fewer dopamine binding sites than those who do not carry the A allele (GG; termed A1‐). We performed a pilot study to assess the association of the rs1800497 ANKK1 c.2137G > A (p.Glu713Lys) variant with weight loss with NB treatment in 33 subjects. Mean (SD) weight loss was 5.9% (3.2%) for the A1+ genotype group (n = 15) and 4.2% (4.2%) for the A1‐ genotype group (n = 18). The mean weight loss for the A1+ genotype group was significantly greater than the predefined clinically significant 4% weight‐loss target (one‐sample t‐test, P = .035), whereas the mean weight loss for the A1‐ genotype group was not ( P = .85). Individuals with the A1+ genotype appear to respond better to NB than A1‐ individuals.Keywords
This publication has 19 references indexed in Scilit:
- TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patientsNutrition, 2012
- The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese womenAppetite, 2012
- D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetesNutrition, 2009
- Relation of reward from food intake and anticipated food intake to obesity: A functional magnetic resonance imaging study.Journal of Abnormal Psychology, 2008
- Relation Between Obesity and Blunted Striatal Response to Food Is Moderated by Taq IA A1 AlleleScience, 2008
- Bupropion Efficacy for Smoking Cessation is Influenced by the DRD2 Taq1A Polymorphism: Analysis of Pooled Data from two Clinical TrialsNicotine & Tobacco Research, 2007
- Association of K121Q polymorphism in ENPP1 (PC-1) with BMI in Caucasian and African-American adultsInternational Journal of Obesity, 2005
- Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1Human Mutation, 2004
- The role of dopamine in motivation for food in humans: implications for obesityExpert Opinion on Therapeutic Targets, 2002
- Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteersMolecular Psychiatry, 1999